AxoGen Soars 10.95% on Analyst Optimism

AxoGen's stock price surged by 10.95% in pre-market trading on May 16, 2025, marking a significant rise for the medical equipment provider.

Analysts have recently adjusted their expectations for AxoGen. Canaccord Genuity Group lowered its target price from $26.00 to $24.00, while maintaining a "buy" rating. This adjustment suggests a potential upside of 103.05% from the company's previous close. Other analysts, such as Cantor Fitzgerald and Lake Street Capital, have also issued positive ratings and price targets for AxoGen, indicating a consensus "buy" rating and an average price target of $22.20.

Insider trading activity has also been noted. Director Amy McBride Wendell sold 5,000 shares, and insider Erick Wayne Devinney sold 15,111 shares, both transactions resulting in a decrease in their ownership stakes. Institutional investors have shown interest in AxoGen, with several hedge funds increasing their positions in the company.

AxoGen specializes in developing and commercializing technologies for peripheral nerve regeneration and repair. The company's product portfolio includes Avance Nerve Graft, AxoGuard Nerve Connector, AxoGuard Nerve Protector, and Axoguard HA+ Nerve Protector, all aimed at addressing various nerve injury and repair needs.